WO2004028472A3 - THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β - Google Patents

THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β Download PDF

Info

Publication number
WO2004028472A3
WO2004028472A3 PCT/US2003/030532 US0330532W WO2004028472A3 WO 2004028472 A3 WO2004028472 A3 WO 2004028472A3 US 0330532 W US0330532 W US 0330532W WO 2004028472 A3 WO2004028472 A3 WO 2004028472A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
therapies
chronic inflammatory
inflammatory demyelinating
demyelinating polyneuropathy
Prior art date
Application number
PCT/US2003/030532
Other languages
French (fr)
Other versions
WO2004028472A2 (en
Inventor
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Alfred Sandrock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT03798770T priority Critical patent/ATE520412T1/en
Priority to US10/529,522 priority patent/US20060182715A1/en
Priority to AU2003277006A priority patent/AU2003277006C1/en
Priority to BR0314548-4A priority patent/BR0314548A/en
Priority to EA200500545A priority patent/EA009289B1/en
Priority to DK03798770.8T priority patent/DK1575531T3/en
Priority to CA002500189A priority patent/CA2500189A1/en
Priority to MXPA05003243A priority patent/MXPA05003243A/en
Application filed by Biogen Idec Inc, Alfred Sandrock filed Critical Biogen Idec Inc
Priority to YUP-2005/0255A priority patent/RS20050255A/en
Priority to SI200332056T priority patent/SI1575531T1/en
Priority to JP2004540030A priority patent/JP2006513990A/en
Priority to EP03798770A priority patent/EP1575531B9/en
Publication of WO2004028472A2 publication Critical patent/WO2004028472A2/en
Priority to IS7746A priority patent/IS7746A/en
Priority to NO20052059A priority patent/NO20052059L/en
Publication of WO2004028472A3 publication Critical patent/WO2004028472A3/en
Priority to US12/944,396 priority patent/US20120058083A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention provides methods for the treatment, and pharmaceuticals for the use in the treatment, of mammalian subjects having, or at risk of developing, chronic demyelinating neuropathies, e.g., CIDP. The methods involve the administration of IFN-β therapeutics.
PCT/US2003/030532 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β WO2004028472A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
YUP-2005/0255A RS20050255A (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha
US10/529,522 US20060182715A1 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss
SI200332056T SI1575531T1 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
EA200500545A EA009289B1 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
DK03798770.8T DK1575531T3 (en) 2002-09-27 2003-09-26 Chronic inflammatory demyelinating polyneuropathy therapies using interferon-beta
CA002500189A CA2500189A1 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-.beta.
MXPA05003243A MXPA05003243A (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-beta.
AT03798770T ATE520412T1 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINIZING POLYRADICUONEUROPATHY WITH INTERFERON-BETA
AU2003277006A AU2003277006C1 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
BR0314548-4A BR0314548A (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelination polyneuropathy using interferon-beta
JP2004540030A JP2006513990A (en) 2002-09-27 2003-09-26 Treatment of chronic inflammatory demyelinating polyneuropathy with interferon beta
EP03798770A EP1575531B9 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
IS7746A IS7746A (en) 2002-09-27 2005-03-15 Treatment of persistent inflammatory demyelinating multiple neuropathy using beta interferon
NO20052059A NO20052059L (en) 2002-09-27 2005-04-27 Chronic inflammatory demyelinating polyneuropathy therapies using interferon-beta.
US12/944,396 US20120058083A1 (en) 2002-09-27 2010-11-11 Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
US60/414,307 2002-09-27

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/529,522 A-371-Of-International US20060182715A1 (en) 2002-09-27 2003-09-26 Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-ss
US9036205A Continuation 2002-09-25 2005-03-25
US12/944,396 Continuation US20120058083A1 (en) 2002-09-27 2010-11-11 Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta

Publications (2)

Publication Number Publication Date
WO2004028472A2 WO2004028472A2 (en) 2004-04-08
WO2004028472A3 true WO2004028472A3 (en) 2006-01-19

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Country Status (21)

Country Link
US (2) US20060182715A1 (en)
EP (1) EP1575531B9 (en)
JP (3) JP2006513990A (en)
KR (1) KR20050059195A (en)
CN (2) CN1802170A (en)
AT (1) ATE520412T1 (en)
AU (1) AU2003277006C1 (en)
BR (1) BR0314548A (en)
CA (1) CA2500189A1 (en)
DK (1) DK1575531T3 (en)
EA (1) EA009289B1 (en)
GE (1) GEP20094699B (en)
IS (1) IS7746A (en)
MX (1) MXPA05003243A (en)
NO (1) NO20052059L (en)
NZ (1) NZ565990A (en)
PL (1) PL377612A1 (en)
RS (1) RS20050255A (en)
UA (1) UA86749C2 (en)
WO (1) WO2004028472A2 (en)
ZA (1) ZA200502416B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
US8920808B2 (en) 2006-10-31 2014-12-30 East Carolina University Cytokine-based fusion proteins for treatment of multiple sclerosis
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina Cytokines and neuroantigens for treatment of immune disorders
SG10201602076QA (en) * 2011-10-01 2016-04-28 Glytech Inc Glycosylated polypeptide and pharmaceutical composition containing same
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520741D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Authentication methods and systems
WO2020009437A1 (en) * 2018-07-04 2020-01-09 서울대학교산학협력단 Immune cell treatment of nerve damage

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (en) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz METHOD FOR THE CONSTRUCTION OF AN ANIMAL CELL LINE FOR THE PRODUCTION OF HUMAN INTERFERON BETA
DE4128319A1 (en) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz NEW RECOMBINANT HUMAN-IFN-BETA, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation Composition for treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
ES2630278T3 (en) * 1998-10-16 2017-08-21 Biogen Ma Inc. Interferon beta-1a polymer conjugates and uses thereof
ES2265693T3 (en) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. FUSION PROTEINS WITH INTERFERON-BETA AND USES.
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
CA2363779A1 (en) * 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
YU48703A (en) * 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
NZ565990A (en) * 2002-09-27 2009-10-30 Biogen Idec Inc Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-beta

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HADDEN R.D.M.: "Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy", NEUROLOGY, vol. 53, 1999, pages 57 - 61, XP008057191 *
VAN DER MEIDE P.H.: "Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats.Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms", JOURNAL OF NEUROIMMUNOLOGY, vol. 84, 1998, pages 14 - 23, XP002992388 *

Also Published As

Publication number Publication date
JP2007039463A (en) 2007-02-15
US20120058083A1 (en) 2012-03-08
JP2006513990A (en) 2006-04-27
NO20052059L (en) 2005-06-27
RS20050255A (en) 2007-08-03
EA200500545A2 (en) 2005-08-25
EP1575531A4 (en) 2008-01-23
NO20052059D0 (en) 2005-04-27
MXPA05003243A (en) 2005-09-12
EA200500545A3 (en) 2007-04-27
CA2500189A1 (en) 2004-04-08
ZA200502416B (en) 2005-10-20
EP1575531B9 (en) 2012-02-22
EP1575531A2 (en) 2005-09-21
KR20050059195A (en) 2005-06-17
IS7746A (en) 2005-03-15
JP2011132248A (en) 2011-07-07
EA009289B1 (en) 2007-12-28
NZ565990A (en) 2009-10-30
EP1575531B1 (en) 2011-08-17
US20060182715A1 (en) 2006-08-17
CN1802170A (en) 2006-07-12
GEP20094699B (en) 2009-06-10
PL377612A1 (en) 2006-02-06
AU2003277006A1 (en) 2004-04-19
CN102038938A (en) 2011-05-04
UA86749C2 (en) 2009-05-25
BR0314548A (en) 2005-08-09
AU2003277006C1 (en) 2010-04-01
DK1575531T3 (en) 2011-11-21
ATE520412T1 (en) 2011-09-15
AU2003277006B2 (en) 2009-09-10
WO2004028472A2 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
NO20052059D0 (en) Chronic inflammatory demyelinating polyneuropathy therapies using interferon-beta.
CA2514473A1 (en) Fused bicyclic nitrogen-containing heterocycles
AU2003239531A1 (en) Protein cages for the delivery of medical imaging and therapy
DK1539166T3 (en) Pharmaceutical compositions containing dextromethorphan and quinidine for the treatment of neurological disorders
IL180992A0 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
MXPA03006863A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors.
DK1465688T4 (en) Bicarbonate-based solutions for dialysis therapy
NO20050497L (en) Use of CETP inhibitors and optionally HMG COA reducible inhibitors and / or antihypertensive agents
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
AU2003225670A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
EA200500764A1 (en) PHARMACEUTICAL COMPOSITIONS AND MEDICAL FORMS FOR TRANSBUCCAL AND SUBLINGUAL DELIVERY TIZANIDINE AND METHODS OF INTRODUCTION TIZANIDINE SUBLINGUAL OR TRANSBUCKAL
HK1063606A1 (en) Medicament containing an effector of the glutathione metabolism together with alpha-lopic acid for use in kidney replacement therapy.
AU2003255989A1 (en) Characterizing, coding and comparing surfaces,contours or boundaries in medical imaging
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003203233A1 (en) N-substituted sulfonamide derivatives and preventive or therapeutic drugs for diabetes containing the same
MY140194A (en) Novel fusidic acid derivatives
AU2003237215A1 (en) Device for using patient blood or blood fractions as diluent in administering pharmaceuticals
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
ATE456573T1 (en) NMB0928 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS
EP1498145A4 (en) DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
TW200510447A (en) Novel fusidic acid derivatives
AU2003258291A8 (en) Htlv-i p30ii and p12i proteins as therapeutic targets in htvl-i infected individuals
ATE444305T1 (en) NMB1125 PROTEIN AND ITS USE IN PHARMACEUTICAL FORMULATIONS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0255

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 167453

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1114/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005/02416

Country of ref document: ZA

Ref document number: PA/a/2005/003243

Country of ref document: MX

Ref document number: 200502416

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2500189

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 377612

Country of ref document: PL

Ref document number: 1020057005145

Country of ref document: KR

Ref document number: 2004540030

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003277006

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 539318

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003798770

Country of ref document: EP

Ref document number: 8765

Country of ref document: GE

Ref document number: 200500545

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038253720

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057005145

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003798770

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006182715

Country of ref document: US

Ref document number: 10529522

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529522

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 10178

Country of ref document: GE